You are here: Industry Insights > HFpEF

News List

The protective effect of soluble guanylate cyclase activators on the cardiovascular system and their therapeutic mechanism for HFpEF Xiaomichong
July 17, 2024
The impairment of the nitric oxide (NO) pathway is closely related to various cardiovascular diseases, such as heart failure, hypertension, and pulmonary hypertension. NO donor drugs or inhaled NO have significant limitations in clinical treatment.
Jardiance becomes first SGLT2 inhibitor to show benefit in HFpEF pharmatimes
July 07, 2021
Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of its SGLT2 inhibitor Jardiance in patients with heart failure with preserved ejection fraction (HFpEF).
AZ says MPO inhibitor AZD4831 shows promise in heart failure study pharmatimes
July 02, 2021
AstraZeneca (AZ) has revealed results from a mid-stage study of its investigational myeloperoxidase (MPO) inhibitor in patients with heart failure with preserved ejection fraction (HFpEF).
Betagenon AB announces investment and collaboration with Hong Kong, S.A.R., China-based MCG Technology Group Ltd prnasia
June 03, 2021
Betagenon AB, a Sweden-based biotech company focused on development of AMPK activator compounds, and MCG Technology Group Ltd, a Hong Kong, S.A.R., China-based biotech investment group, announced that MCG Technology Group will invest in and collaborate wi